March 2025 Life Sciences Update

Germany: Munich

MARKETS CONTENTS

Market Summary

Public & Private Funding (2024)

Fast Lab Stats

• The Munich investment market reached a volume of 2.25 billion euros in 2024, a 90% increase from the previous year. Investor interest has increased since 2023, as investors expect pricing to be already at the start of the new cycle. A stabilization in yields can be observed. • International capital sources show great interest in life sciences investments in Munich. However, there is a lack of available product of existing properties and of adequate development plots at attractive prices. The suburbs of Munich, such as Planegg-Martinsried and Freising, are in high demand from both SMEs and international companies seeking co-operational projects on-site. • Munich is one of the leading biotechnology locations in Germany. The focus of the established life sciences companies is primarily in the pharmaceutical medical sector. More than half (55%) of total employees in the life sciences sector work in the field of biotechnology, almost doubling in the past eight years. • Munich benefits from the excellent networking between research institutes and industry. Several medium-sized biotechnology companies are spinoffs of scientific institutions. The existing research institutions, as well as the university landscape (Max Planck Institute, Helmholtz Centre, LMU and TU Munich), also promote the settlement of new companies and startups. With two established biotechnology innovation and startup centers (IZB) in Martinsried and Freising, Munich possesses attractive and modern laboratory and office space.

€ Raised (MM)

Company

Deal Type

Completed

VC Round

33.4K Total Life Sciences Employment 450 Life Science Companies 25 Research facilities/ institutes

CPTx

Early Stage VC

Sep 2024

1st Round

€ 29.0

Puray

Accelerator/Incubator

Mar 2024

€ 0.01

Ventra

Seed Round

Jan 2024

1st Round

€ 0.01

2NA FISH

Accelerator/Incubator

Mar 2024

Crane Biosciences

Early Stage VC

Jan 2024

2nd Round

Serino

Accelerator/Incubator

May 2024

Ventra

Accelerator/Incubator

Jun 2024

Representative Investment Sale Transactions (2023 – 2024)

Address

Type

Volume (€m)

GLA (sqm)

Date Buyer

Life Science Center Martinsried Lab/Office

Confidential

6,000 Q1 2024 Aventin RE

Lindberghstraße 25, Munich

Lab/ Office/ Production

Confidential

11,300 Q4 2023 Beos

Zielstattquartier, Sendling

Office

c. 90

18,500 Q3 2023 Sonar/GIC

Representative Life Sciences Companies

Life Sciences Labor: Annual Chemist Job Postings

1,400

Company

Type

1,200

Amgen

Biotechnology

Representative Lease Transactions (2023 – 2024)

1,000

Company

Address

GLA (sqm)

New/Renewal

Type

Quarter

Landlord

Aenova

Pharma

800

Medtronic

Landsberger Straße 344-354

3,770 New letting

Office

Q4 2024 Axa Investment

600

Pfizer

Biotechnology, Pharma

Biontech

Gisela-Stein-Straße

3,500 New letting

Office

Q1 2024 Patritzia Deutschland

400

ICU Medical

Bretonischer Ring 10-12

3,068 New letting

Office

Q3 2024 Unknown

Sanofi

Pharma

200

Tilibit Nanosystems South Horizon, Koppstrasse 4

1,600 New letting

Office

Q1 2023 Confidential

Roche Diagnostics

Pharma

-

Immatics Biotech

Machtlfingerstraße 5-15

1,348 New letting

Office

Q4 2024 Barings Real Estate

2019

2020

2021

2022

Mbiomics

Floriansbogen 4

1,300 New Letting

Office

Q2 2023 Unknown

Plectonic Biotech

Skygate, Zeppelinstraße 1-3

650 New letting

Office

Q1 2024 Rock Capital

Bio Degree-Awarding Institutions, Metro Area

Ludwig-Maximilians-Universtiät Technische Universität München

• •

Contributors Benedikt Kiefer benedikt.kiefer@cushwake.com

Simon Jeschioro simon.jeschioro@cushwake.com

Sources: Cushman & Wakefield Research, CoStar, National Institutes of Health (NIH), Lightcast, Pitchbook, Federal Reserve Economic Data (FRED)

Cushman & Wakefield

85